ClinicalTrials.gg
Status unknownNCT04824976Updated Apr 1, 2021

Effects of Blueberries on Symptoms and Underlying Mechanisms of Functional Gastrointestinal Disorders

An interventional study of Blueberry and Placebo in Functional Gastrointestinal Disorders, sponsored by Brain-Gut Research Group. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-04-01.

Sponsored by Brain-Gut Research Group · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

There is extensive pre-clinical evidence for potential health effects of blueberries. These are related, but not exclusively due to their high polyphenol content. This translational, clinical, randomized, cross-over, double-blind, placebo-controlled study will investigate the effects of blueberries in freeze-dried powder form on gastrointestinal and extra-gastrointestinal symptoms and function, as well as specific potential underlying mechanisms, in patients with the overlapping functional gastrointestinal disorders, irritable bowel syndrome and functional dyspepsia.

02

Conditions studied

  • Functional Gastrointestinal Disorders
03

In context

Gastrointestinal Diseases

548 studies on the registry are indexed under Gastrointestinal Diseases; 101 are open to participants now.

This study's planned enrollment of 55 is below the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.

Browse Gastrointestinal Diseases studies →

Lead sponsor

Brain-Gut Research Group is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fifty-five successive male or female patients with Functional Gastrointestinal Disorders FGID) enrolled from our Gastroenterology Group Practice (GGP) in Bern, Switzerland, classified as having either Irritable Bowel Syndrome (IBS), Functional Dyspepsia (FD) or both according to Rome 4 criteria (Drossman et al 2016; Schmulson et al. 2017)
  • Age between 18 and 50 years
  • 18.5-29.9 kg/m2
  • European / Caucasian ethnicity
  • Able to give in German as documented by signature

Exclusion criteria

Exclusion Criteria:

  • Evidence of disease, as assessed by usual clinical practice (history, blood and stool tests, imaging and endoscopy, as clinically required) and by investigator.
  • Colonoscopy, antibiotics or probiotics within 2 weeks before or during the study.
  • Planned dietary modifications (including polyphenol-rich fruit or vegetable smoothies, drinks or diets) or initiation of new treatments during the study period, besides the study interventions.
  • Inability or to undergo the investigated intervention
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (estimated)

Study arms

  • Active comparator
    Blueberry

    Freeze-dried pure blueberry powder

    Dietary Supplement: Blueberry

  • Placebo comparator
    Placebo

    Maltodextrin powder.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementBlueberry

    freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal

  • Dietary supplementPlacebo

    matched powder maltodextrin twice daily = 60kcal

06

What researchers measure

Primary outcomes

  1. Change in Gastrointestinal Symptom Rating Scale (GSRS)

    Validated scale of GI symptoms

    Time frame: before and after 6 weeks of each treatment arm

Secondary outcomes

  1. Change in cognitive neurological function tests

    Cambridge Cognition neurocognitive test battery (CANTAB)

    Time frame: before and after 6 weeks of each treatment arm

  2. Change in musculoskeletal symptoms

    Validated Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) scores

    Time frame: before and after 6 weeks of each treatment arm

  3. Change in breath gas concentrations and symptoms scores during fructose breath testing

    AUCs (areas under curve) of hydrogen, methane and symptom scores during fructose breath tests

    Time frame: before and after 6 weeks of each treatment

  4. Change in laboratory markers for advanced glycation end products, tight junction proteins

    Validated biochemical markers of advanced glycation, tight junction protein quantification

    Time frame: before and after 6 weeks of each treatment

07

Study locations

1 of 1 sites recruiting
  • Gastroenterology Group Practice / Brain-Gut Research Group
    Bern, 3011, Switzerland
    Recruiting
    • Clive Wilder-Smith, MD · Contactinfo@ggp.ch · +41313123737
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2021, 23 months after the start.

Of 127 non-industry interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 23 months is below that.

Counting every sponsor, half of 149 studies reached it within 24 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2020
First posted
Apr 1, 2021
StartActual
Jan 1, 2020
Primary completionEst.
Dec 31, 2021
CompletionEst.
Apr 1, 2022
Last update
Apr 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04824976
Lead sponsor
Brain-Gut Research Group
Responsible party
Clive H Wilder-Smith, MD (Dr, Brain-Gut Research Group) — Principal investigator
First posted
Apr 1, 2021
Start date
Jan 1, 2020
Primary completion
Dec 31, 2021 (estimated)
Completion
Apr 1, 2022 (estimated)
Last update
Apr 1, 2021

Study contacts

Clive Wilder-Smith, MD
Contact
info@braingut.com
+41313123737

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blueberry extract

Start the discussion